Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB): a Randomized, Double-blind, Placebo-controlled, Proof-of-concept Clinical Trial

NCT01638520 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT01638520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01638520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB): a Randomized, Double-blind, Placebo-controlled, Proof-of-concept Clinical Trial
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2012
Completion date
July 31, 2017
Enrollment
32 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis, pulmonary